APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

NCT02706353 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Stopped \<75% participant accrual

Conditions

Melanoma

Interventions

DRUG: APX005M
DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]